Komori
JCR Pharmaceuticals (4552) · RiskMitigated

Business Risks Including Natural Disasters, Competition, Side Effects and Partnership Dissolution

First written in FY2016. 1 of 3 entries say "Reframed", first in FY2019. Latest entry: FY2020.

3entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016ReframedFY20192016: 120162017: 020172018: 020182019: 120192020: 12020
Same theme, other companies
Business continuity risk from litigation, disasters, and dependence on licenses from other companiesA theme 4 companies write about · 4 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2020MitigatedAnnual report

    「By acquiring U.S.-based ArmaGen in April 2020, the Company obtained intellectual property rights relating to technology for crossing the blood-brain barrier in the United States and elsewhere. The Company currently assesses the risk of infringing third-party intellectual property rights relating to this technology as low.」

    Specified the risk of intellectual property infringement and stated that the Company assesses the current infringement risk as low because it acquired the relevant intellectual property through the acquisition of ArmaGen.
  2. FY2019ReframedAnnual report

    「In addition to the above, various risks exist, including delays or stoppages in business activities due to natural disasters and other events, interruptions to raw material procurement, infringement of intellectual property rights, environmental issues, concerns regarding product safety and quality, the emergence of adverse effects, changes in the product environment such as intensifying competition, the termination of licenses or alliances, system failures, information leaks and the filing of lawsuits. The risks listed here do not constitute all of the Group's risks.」

    Reorganized the risk items by adding intellectual property rights, the environment, product quality, system failures and information leaks to the previously listed risks such as natural disasters, competition, adverse effects and the dissolution of alliances.
  3. FY2016First statedAnnual report

    「In addition to the above, various risks exist, including delays or stagnation in production activities due to natural disasters and other events, intensifying competition with other companies, the emergence of adverse effects, the termination of licenses or alliances, interruptions to overseas procurement of raw materials, the filing of lawsuits and foreign exchange rate fluctuations. These risks may affect the Group's operating results and financial position.」

    Provides a comprehensive list including natural disasters, production disruptions, competition, adverse effects, the dissolution of alliances, interruptions to raw material procurement and litigation.
Moved together

"Voluntary Recall of the "BabySenseTM" Apnea Alarm and Related Losses" moved the same way as this thread, in the same document, in 2 of its 3 moves.

2★1
  1. ★This thread
  2. 1Voluntary Recall of the "BabySenseTM" Apnea Alarm and Related Losses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Business Risks Including Natural Disasters, Competition, Side Effects and Partnership Dissolution | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori